NASDAQ:ELYM Eliem Therapeutics 8/14/2024 Earnings Report $1.26 -0.02 (-1.56%) As of 06/13/2025 ProfileEarnings History Eliem Therapeutics EPS ResultsActual EPS-$1.81Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEliem Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEliem Therapeutics Announcement DetailsQuarterDate8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Eliem Therapeutics Earnings HeadlinesClimb Bio Reports Increased Losses Amid Ongoing DevelopmentMay 16, 2025 | tipranks.comEliem Therapeutics (NASDAQ:ELYM) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comAnother market crash is coming - here's whenMagnificent 7 Wipeout: What's Next? The first quarter stock crash and quick recovery has many people confused. And the coming months are critical. You need a big-picture plan... and you need to take specific actions starting TODAY. 50-year Wall Street veteran Marc Chaikin recently published his full big-picture plan, which lays out – based on more than 100 years of data – exactly what you can expect in the markets this year (and in 2026, too).June 16, 2025 | Chaikin Analytics (Ad)Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.October 2, 2024 | globenewswire.comEliem Therapeutics: Recent Strategic Pipeline RestructuringSeptember 23, 2024 | seekingalpha.comEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitSeptember 11, 2024 | globenewswire.comSee More Eliem Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eliem Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eliem Therapeutics and other key companies, straight to your email. Email Address About Eliem TherapeuticsEliem Therapeutics (NASDAQ:ELYM), a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.View Eliem Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
